Skip to main content
. Author manuscript; available in PMC: 2013 Jun 13.
Published in final edited form as: Drug Metabol Drug Interact. 2013;28(1):59–63. doi: 10.1515/dmdi-2012-0031

Table 2.

Combined CYP3A4/5 genotype and dose levels.

Poor metabolizers per dose level
Intermediate metabolizers per dose level
Extensive metabolizers per dose level
n ≤10 mg 20 mg ≥40 mg ≤10 mg 20 mg ≥40 mg ≤10 mg 20 mg ≥40 mg
Atorvastatin 142 5 (45%) 4 (36%) 2 (18%) 27(27%) 28 (28%) 46 (46%) 5(17%) 11(37%) 14 (47%)
Simvastatin 84 2(29%) 3 (43%) 2 (29%) 4 (7%) 18 (31%) 36(62%) 2(11%) 6 (32%) 11 (58%)

Data for each dose level represents the number of patients and percentage of the combined genotype group at the specified dosing level.